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SUMMARY 
Using solid state radioimmunoassays developed by the first author, changes in the 
urine level of plasmin-like substances (PLS) and fibrin degradation products (FDP) 
before and after human kidney transplantation were determined in 49 transplant 
patients. Averages of urine PLS and FDP in a normal population of 51 persons were 
0.13 ± 0.10 (SD) and 0.14 ± 0.07 JLg/ml, respectively. In all transplant patients there 
was an initial rise of both PLS and FDP in urine immediately after transplantation. 
This elevation peaked on days 4 and 5 and the PLS and FDP levels returned to normal 
range within 2 weeks in patients without evidence of rejection. A secondary rise of 
urine PLS was detected before or with a rise in serum creatinine in all of the patients 
experiencing rejections. Of 11 patients who showed a rejection episode within 2 weeks 
of transplantation, the secondary rise of urine PLS was detectable in 55% of the 
patients slightly before the serum creatinine level changes; of 6 patients with a 
rejection episode more than 2 weeks after transplantation, 100% showed a secondary 
PLS rise 6.7 ± 2.3 (SE) days before the serum creatinine increased. The appearance of 
the secondary rise of urine FDP in the rejecting recipients was slightly later than the 
rise of PLS. Serial determination of urine PLS levels following human kidney trans-
plantation appears to be an early index of rejections which occurs more than 2 weeks 
after transplantation, although the clinical usefulness of this measurement is proba-
bly limited. 
Several reports indicate that following hu-
man kidney transplantation fibrin degradation 
products (FDP) appear in urine and that the 
amount of urine FDP increases during graft 
rejection (1-3, 5, 9, 21, 25). It has been sug-
gested that the appearance of FDP in urine is 
the result of the digestive effect of plasmin on 
fibrin which has been deposited on kidney 
capillary beds during rejection (J;!5). To date, 
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urine plasmin or plasminogen levels after kid-
ney transplantation have not been studied. A 
very sensitive radioimmunoassay system (solid 
state radioimmunoassay) has been develbped 
by the first author in order to measure sub-
stances which have common antigenicity to 
heterologous antiplasminogen antibodies. U s-
ing this assay, changes in the levels of these 
plasmin-like substances (PLS) in urine before 
and after human kidney allotransplantation 
have been studied and correlated with FDP 
levels and with rejection episodes. 
MATERIALS AND METHODS 
Patients. Forty-nine kidney transplants were 
studied. Sixteen patients received kidneys from 
living related donors and 33 from cadaveric 
donors. The recipients were treated with triple 
immunosuppressive therapy consisting of cyclo-
phosphamide or azathioprine, prednisone, and 
antilymphocyte globulin. The onset of rejec-
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tion was designated as the day when serum 
creatinine was considered to have increased 
. significantly. Increase of urine protein and de-
crease of urine sodium or urine volume were 
considered supporting evidence for rejection. 
Serum creatinines and other renal chemical 
parameters of rejection were measured daily 
during the first 4 weeks after transplantation 
and less frequently thereafter. The end of a 
rejection episode was designated as the day 
when the elevated serum creatinine level be-
gan to fall. The patients were followed for up to 
7 months after transplantation. The recipients 
were divided into five groups: group 1, no rejec-
tion episode during the observation period; 
group 2, doubtful rejections; group 3, rejection 
episodes within 2 weeks of transplantation; 
group 4, rejection episode after more than 2 
weeks following transplantation; and group 5, 
serious postope;-ative complications of any kind 
regardless of rejections. 
Urine collections. The urine was collected for 
testing in almost all cases at least once before 
transplantation, three times per week for 2 
weeks after transplantation, and twice per 
week thereafter. The first morning urine was 
collected in a test tube containing E-aminoca-
proic acid (EACA) at a concentration of 2.5 mgt 
ml of urine and kept at 4 C for a few hr. The 
sample was centrifuged at 4,000 rpm for 10 min 
at 4 C and the supernatant was stored at -70 C. 
Urine containing gross blood was excluded. 
Radioiodination of rabbit anti-human plas-
minogen JgG with 12f>iodine. Rabbit anti-hu-
man plasminogen IgG was extracted from com-
mercial antisera (Behring Diagnostic, Ameri-
can Hoechst Corp., Woodbury, New York) us-
ing one-third saturated ammonium sulfate pre-
cipitation followed by DEAE cellulose (What-
man DE32; H. Reeve Angel Inc., London, Eng-
land) column chromatography with phosphate 
buffer, pH 8.0, 0.005 M. Radioiodination with 
125iodine (Amersham/Searle Corp., Des 
Plaines, Illinois) of the rabbit anti-human plas-
minogen IgG was done according to Green-
wood's method (7). The sp~cific activity of the 
labeled IgG was 0.72 to 0.80 mc/mg. The labeled 
IgG produced only one precipitin band in ra-
dioimmunodiffusion in agar (23) against nor-
mal human plasma as well as against a stan-
dard human plasminogen (American National 
Red Cross, New York, New York). 
Solid state radioimmunoassay for PLS. PLS 
in urine samples was radioimmunoassayed us-
ing Mori's method (19) with modifications, 
which was originally developed for measuring 
antimicrosomal and antithyroglobulin antibod-
ies. Each well of a disposable microtiter plate 
(Cooke Engineering Co., Alexandria, Virginia) 
was filled with normal human serum which 
had been diluted 1:50 with carbonate-bicarbon-
ate buffer (pH 9.0, 0.02 M) containing 0.25% 
EACA. Three wells of the plate were used as a 
control filled with only the buffer. The plate 
was placed in a humid box at 25 C for 2 hr and 
then washed three times with Tris-glycine-
phosphate saline (TGPS) (pH 7.6; 0.025 M Tris-
0.025 M glycine-0.02 M KH2P04-O.9% NaCl). 
The wells were filled with TGPS containing 1 % 
bovine serum albumin (BSA) and 0.01 % horse 
y-globulins (HGG), then the plate was incu-
bated for 20 min in the same way as above and 
washed three times with TGPS. The plates 
coated with human serum could be kept in a 
humid box at 4 C for several hr without damag-
ing the antigenic activity of the coated proteins. 
Standard plasminogen solution (original con-
centration, 1.8 mg/ml) was serially diluted by 
TGPS containing 2% BSA-0.02% HGG and 
0.25% EACA. Standard mixtures and sample 
mixtures were made as follows: 5 volumes of 
each of the diluted standard plasminogen, plus 
1 volume of 125iodine-labeled antiplasminogen 
IgG in TGPS at a concentration of3.6 to 4.0 ILC/ 
ml, plus 3 volumes of TGPS. The final concen-
trations of the standard plasminogen ranged 
between 8.0 and 0.002 ILg/ml. One of the stan-
dard mixtures was made containing no plas-
minogen. Sample mixtures were prepared so 
that urine was diluted 1:9, using 1 volume of 
urine, 5 volumes of TGPS containing BSA, 
HGG, and EACA, 1 volume of the labeled IgG, 
and 2 volumes of TGPS. When the PLS level of 
the sample examined exceeded 8.0 ILg/ml, the 
sample was appropriately diluted with TGPS. 
The mixtures were incubated at 25 C for 1 hr, 
then 250 ILl of each mixture were transferred in 
triplicate to the plate already coated by normal 
human serum. The standard mixture contain-
ing no plasminogen was put in both the serum-
coated wells (positive control) and the uncoated 
wells (negative control). The plate was incu-
bated at 25 C for 20 hr in a humid box. The 
mixtures were removed by suction and the 
plate was washed with tap water. After drying, 
each well was separated and the radioactivities 
of the wells were counted with a crystal well-
type gamma counter (Beta/Gamma Liquimat; 
--""-------"-"------------------------
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Picker Nuclear, White Plains, New York). E-
aminocaproic acid inhibits the activity of plas-
minogen activator and plasmin, which could 
affect the assay. Bovine serum albumin is gen-
erally used as a stabilizer in radioimmunoas-
says. Horse y-globulin in sample mixtures in-
hibits cross-reaction of antihorse y-globulin an-
tibody against 125I-Iabeled rabbit anti-human 
plasminogen IgG. Because many of the patients 
were treated with horse anti-human antilym-
phocyte globulin, some may have had antibod-
ies against horse globulin. 
Calculation of the urine PLS concentration 
was performed in the following way: positive 
control count minus negative control count was 
defined as 100% net bound count in each plate. 
Per cent bound of standard mixtures or sample 
mixtures was determined by the following for-
mula: 
standard or sample count 
- negative control count 
----------x 100 
100% net bound count 
A standard curve was made from the percent-
age bound for each standard mixture. The PLS 
concentration of each sample was determined 
from the standard curve. Although each plate 
gave a slightly variable count even for the same 
sample, this variability in counts was elimi-
nated by using the above defined calculation for 
the percentage bound. The sensitivity of the 
assay was determined and 0.02 Itg/ml of plas-
minogen in the standard mixture was found to 
be the minimum amount detectable. Four 
kinds of dilutions of a sample were assayed six 
times to study reproducibility of this method. 
Mean values and standard deviations of each 
dilution were 0.38 ± 0.05, 0.97 ± 0.01, 4.0 ± 
0.74, and 10.3 ± 1.1 (ltg/mI). 
Radioimmunoassay for FDP. The principle 
of the radioimmunoassay for FDP was the same 
as that for PLS, but there were several differ-
ences in the assays. Antifibrinogen IgG was 
extracted from commercial rabbit anti-human 
fibrinogen antisera (Behring Diagnostics). The 
specific activity of the antifibrinogen IgG la-
beled with 125iodine was 0.9 mc/mg, and for the 
radioimmunoassay the labeled IgG was diluted 
to 2.5 Itc/ml with phosphate-buffered saline 
(PBS), pH 7.6, 0.02 M. Human fibrinogen (Nu-
tritional Biochemicals Corp., Cleveland, Ohio) 
was diluted to the concentration of 0.5 mg/ml 
with carbonate-bicarbonate buffer (pH 9.6; 
0.002 M), filtered through Whatman No.1 pa-
per, and used for coating microtiter plates. PBS 
was used for diluting media instead of TGPS. 
For making standard fibrinogen solution, hu-
man fibrinogen in PBS was gel-filtered through 
Sephadex G-200 (Pharmacia, Piscataway, New 
Jersey) and the filtrate of the first main peak 
was collected. After arrangement of the protein 
concentration at 3.4 mg/ml, the fibrinogen solu-
tion was serially diluted by PBS containing 2% 
BSA, 0.02% HGG, and 0.25% EACA. The final 
concentrations of the fibrinogen in standard 
mixtures were 15.1 to 0.038 Itg/ml. The mini-
mum amount of fibrinogen detected by this 
method was found to be 0.08 Itg/ml. The repro-
ducibility of this assay was slightly better than 
for the plasmin assay. 
RESULTS 
Normal level and preoperative range. Aver-
ages of urine PLS and FDP in a normal human 
population of 51 persons were 0.13 ± 0.12 (SD) 
and 0.14 ± 0.07 Itg/ml, respectively. Preopera-
tive levels of urine PLS and FDP in 14 primary 
transplant patients were very variable, rang-
ing from 0.14 to 11.7 Itg/ml for PLS and 0.38 to 
46.0 Itg/ml for FDP. 
Group 1. Of the 49 transplants, 21 had no 
rejections during the observation period. In all 
21 patients, an elevation of urine PLS was ob-
served starting on 1 day after transplantation 
and lasting for 4 to 5 days, then falling gradu-
ally (Fig. 1). The average value of urine PLS 
was 3.16 ± 4.80 (SD) Itg/ml for the first 5 days, 
0.86 ± 1.25 from the 6th to 10th days, 0.40 ± 
0.26 for the 11th to the 15th day, 0.26 ± 0.12 
from the 16th to 20th day, and 0.26 ± 0.11 
thereafter. Except for two patients, the urine 
PLS values were stabilized at a lower level 
than 0.5 Itg/ml within 14 days following trans-
plantation. The general pattern of urine FDP 
in this group was similar to that ofPLS (Fig. 2). 
Group 2. Of the 49 transplants, 3 had rejec-
tion episodes which were only suspected by 
renal function tests. However, urine PLS re-
mained higher than 0.5 Itg/ml for all of the 
patients for more than 14 days following trans-
plantation. The urine PLS pattern was very 
similar to that of group 3, which had a rejection 
episode within 2 weeks after transplantation. 
Group 3. There were 13 cases with definite 
rejection episodes within 2 weeks of transplan-
tation. The urine PLS pattern (Fig. 3) was 
quite different from that seen in group 1. The 
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FIGURE 1. Urine PLS levels (/Lg/ml) in 21 patients 
with no observed rejection episodes. Mean values 
before transplantation and at intervals after trans-
plantation are indicated (x--xl. 
initial rise of urine PLS immediately after 
transplantation was followed by a secondary 
rise, which appeared shortly before or almost at 
the same time as when the serum creatinine 
level started to increase. The mean difference 
in time between the secondary rise in urine 
PLS and the elevation of serum creatinine in 11 
of the 13 cases was 0.3 ± 0.6 (SE) days (Table 1). 
The secondary rise ofPLS exceeded 0.5 fLg/ml of 
urine in all of the 13 cases and exceeded 10 fLg/ 
ml in 4 cases. Almost simultaneously with the 
end of rejection this secondary elevation disap-
peared, except for one patient in whom it re-
mained elevated even after renal function had 
recovered. The urine FDP pattern in this group 
was the same as the PLS, except that the sec-
ondary rise of FDP level usually did not occur 
earlier than the onset of rejection. The FDP 
level was over 2.0 p.g/ml during the rejection 
episodes except for one case. 
Group 4. There were 12 cases with a rejection 
episode more than 2 weeks after transplanta-
tion. In all 12 patients, urine PLS level became 
normal after the initial rise following trans-
plantation and then elevated to a level of more 
than 0.5 p.g/ml when the rejection was evident 
by renal function tests. With six patients whose 
samples were available for examination within 
3 days before the onset of rejection, the time 
relationship of the secondary rise in urine PLS 
to the onset of rejection was examined (Fig. 4). 
All six patients showed a secondary elevation, 
which appeared defmitely before serum creati-
nine criteria gave evidence of rejection. The 
mean difference in time between the rise in 
urine PLS and serum creatinine was 6.7 ± 2.3 
(SE) days (Table 1). The pattern ofFDP of this 
group was again similar to that of PLS, but the 
elevation of FDP started a few days later than 
PLS; the FDP value during rejection exceeded 
20 p.g/ml for HJ of the 12 patients. 
Group 5. There were eight patients who had 
major complications after transplantation: one 
lung infection attributable to cytomegalovirus, 
two acute tubular necroses, and five complica-
tions requiring operative intervention includ-
ing one gastrectomy, one amputation of a lower 
leg, and three operations for urological compli-
cations. Urine levels of PLS and FDP did not 
change in the patient with cytomegalovirus in-
fection, but they were markedly elevated with 
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FIGURE 2. Urine FDP levels (/Lg/ml) in 21 patients 
with no observed rejection episodes. Mean values 
before transplantation and at intervals after trans-
plantation are indicated (x--x). 
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FIGURE 3. Urine PLS levels (lLg/ml) in 13 patients 
with initial rejection episodes during the first 2 
weeks after transplantation. The time of onset of 
rejection was determined by initial rise of serum 
creatinine. The end of each rejection episode as mea-
sured by fall of serum creatinine is indicated ( t ). 
acute tubular necrosis and slightly elevated 
after secondary surgical procedures. Three pa-
tients had a rejection episode concomitant with 
these complications, and elevation of urine PLS 
and FDP was observed with these rejections. 
Predictability of rejection according to PLS 
and FDP determinations. In order to see the 
efficiency of urine PLS and FDP determina-
tions in predicting rejection episodes, the day 
on which the secondary rise in PLS and FDP 
was detected for the first time was compared 
with the day of the onset of rejection judged by 
the change in serum creatinine level in groups 
3 and 4 (Table 1). Two of the 13 patients in 
group 3 were excluded from this analysis be-
cause of nonavailability of urine samples 
within 3 days prior to rejection. Of the remain-
ing 11 patients, 6 (55%) demonstrated a detecta-
ble rise of PLS at a slightly earlier time than 
the rejection was diagnosed by serum creati-
nine criteria; in these 11 cases the mean differ-
ence in time between the rise in urine PLS and 
serum creatinine was 0.3 ± 0.6 (SE) days. The 
elevation of urine FDP in this group was de-
tected later than the serum creatinine increase 
in 8 of the 11 patients, which made the time 
difference -0.7 ± 0.7 days. Six patients from 
group 4 were available for this comparison. In 
all six cases, the urine PLS elevation preceded 
a rise in serum creatinine by a mean of 6.7 ± 
2.3 days. Three ofthe six cases showed an ele-
vation in urine FDP which preceded a rise in 
serum creatinine. The mean difference in time 
between the elevation of urine FDP and rise in 
serum creatinine in these six patients was 2.5 
± 1.2 days. The relative ability of urine PLS 
versus FDP determinations to predict rejection 
in these six patients was not statistically differ-
ent (P < 0.20). 
DISCUSSION 
Because there is no effective therapy for hy-
peracute or chronic rejection, most of the tests 
that have been developed to detect rejection are 
directed at identifying acute rejection episodes, 
which may be reversible by treatment with 
corticosteroid and possibly by graft radiother-
apy. Numerous immunological tests have been 
devised for this purpose, including leukocyte 
aggregation tests (10), spontaneous blastogenic 
transformation (16), peripheral mononuclear 
cell RNA synthesis (22), leukocyte migration 
inhibition (24), mixed leukocyte culture inhibi-
tion (26), and changes in serum immunoglobu-
lin and complement levels (15,30). A number 
of other tests for rejection have been devised 
which generally depend on looking at the prod-
ucts of secondary damage to the graft, includ-
ing lysozymuria (8), elevation of blood and uri-
nary histamine (J 8), and increased urinary 
FDP (1--3, 5, 9, 21, 25). Renal biopsies have 
been studied for this purpose (17), but there is 
no morphological finding that is completely 
specific for rejection. 
The clinician still relies heavily on physiolog-
ical tests of graft function for making a diagno-
sis of rejection. Oliguria, increased serum cre-
atinine, and decreased creatinine clearance are 
the most useful clues to rejection, but obstruc-
tive uropathy and major vascular occlusion 
must be eliminated from the differential diag-
nosis before the exclusion diagnosis of rejection 
becomes tenable. It is generally agreed that 
acute rejection should be treated as promptly as 
possible. It is therefore important to continue to 
search for tests for rejection which can detect 
this process more specifically and earlier than 
current methods. 
Changes in urine level of PLS and FDP be-
fore and after kidney transplantation were ana-
lyzed for this purpose. In all patients with 
transplants, an initial rise of both PLS and 
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TABLE 1. Time of elevation of serum creatinine, urine PLS, and urine FDP in 17 patients with definite 
rejection episodes 
Patients Donor source Serum cre-
atinine ele-
vation 
Days after transplantation 
Urine PLS ele-
vation 
Urine FDP ele-
vation 
Group 3 (Rejection within 2 weeks after transplantation) 
C. D. (2nd transplantation) Cadaveric 8 5 5 
6 
20 
6 
7 
13 
J. H. Cadaveric 6 3 
M. G. (3rd transplantation) Cadaveric 14 13 
M. L. Cadaveric 7 6 
E. P. Cadaveric 8 7 
C. M. Cadaveric 10 9 
C. D. Cadaveric 5 5 5 
D. I. Living Related 7 8 8 
D. J. Cadaveric 9 10 10 
G. S. Cadaveric 7 9 9 
J. H. Living Related 14 17 14 
-0.7 ± 0.7 a 0.3 ± 0.6a 
Group 4 (Rejection after 2 weeks following transplantation) 
M. L. (2nd rejection) 
M. L. (3rd rejection) 
M.G. 
Cadaveric 39 22 35 
53 
20 
19 
15 
24 
A. F. 
B. S. 
F. D. 
Cadaveric 
Cadaveric 
Cadaveric 
Cadaveric 
Cadaveric 
60 
20 
19 
15 
28 
53 
13 
15 
11 
27 
6.7 ± 2.3" 2.5 ± 1.2" 
a The mean difference in time (days) between the onset of rejection measured by initial rise of serum 
creatinine and the onset of rejection measured by rise of urine PLS or urine FDP (mean ± SE). 
FDP immediately after transplantation was ob-
served. This elevation peaked on days 4 and 5 
and the level returned to normal range within 2 
weeks in patients without evidence of rejection. 
When patients had a rejection, urine PLS level 
exceeded 0.5 fLg/ml of urine in all cases and the 
FDP level exceeded 2.0 J.Lg/ml in 88% of the 
rejecting patients. The group of patients in 
which the urine PLS level provided the most 
useful information for an early diagnosis of re-
jection was those patients who experienced a 
rejection episode after more than 2 weeks fol-
lowing transplantation (group 4). In all six pa-
tients in this group which were available for 
the early diagnostic studies, the urine PLS ele-
vation preceded the rise in serum creatinine by 
an average of 6.7 ± 2.3 (SE) days. In contrast 
with this, only 50% of the patients from this 
group showed the FDP elevation which ante-
dated the rise in serum creatinine. With pa-
tients whose rejection occurred within the first 
2 weeks following transplantation (group 3), 
the urine PLS and FDP assays were less fre-
quently able to predict rejection, i. e., 55 % for 
PLS and 27% for FDP. Both the PLS and FDP 
assays were not capable of distinguishing rejec-
tion from acute tubular necrosis (group 5). The 
precise mechanism of PLS excretion of urine 
during acute rejection remains uncertain. An 
initial process of the acute rejection is pre-
sumed to be destruction of vascular endothelial 
cells in graft tissue by both antibodies and lym-
phocytes against histocompatibility antigens. 
In this process, plasminogen would be activated 
into plasmin by plasminogen activator released 
from the injured endothelial cells (20, 28), 
which contain much ofthe plasminogen activa-
tor (12,29). The injury of the endothelial cells 
causes platelet aggregation and fibrin clotting 
(4, 11). The Hegeman factor (14) and fibrin 
produced in this process can also stimulate the 
PLS system. In addition, blood flow retardation 
by the platelet aggregation and fibrin clotting 
results in tissue ischemia. The plasminogen 
activator is released from the ischemic tissues 
(13,14). As a result, the amount of PLS would 
increase in the graft as well as in the circulat-
ing blood (6), and the PLS would act on fibrin 
to give rise to FDP. 
The PLS level in urine depends on possibly 
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FIGURE 4. Urine PLS levels (fLg/ml) in six pa-
tients who had a rejection episode which began more 
than 2 weeks after transplantation. The time of 
onset of rejection was determined by initial rise of 
serum creatinine. The end of each rejection episode 
as measured by fall of serum creatinine is indicated (n 
both abnormal production of the PLS in the 
transplanted kidney and abnormal filtration of 
these proteins through damaged glomeruli. 
The molecular weight of plasmin monomer is 
approximately 32,000 (27) and is much smaller 
than those of FDP and albumin. Only the mon-
omer type of plasmin is detected in vivo (Y. 
Takeda, personal communication). It would not 
be unreasonable to assume that a large amount 
of the small molecules produced in the grafted 
tissue could easily appear in urine at an early 
stage of rejection. In fact, urine PLS tended to 
be detected earlier than urine FDP in this 
study and there was no correlation between the 
amount of PLS and total proteins in urine after 
kidney transplantation. 
The time needed for the determination of 
urinary PLS levels, approximately 25 hr, par-
tially limits the clinical value ofthis test. If the 
plate incubation time can be shortened, the 
clinical usefulness of this assay may be in-
creased. 
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